Linked Life Data

1918387

Source:http://linkedlifedata.com/resource/pubmed/id/1918387

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1991-11-1
pubmed:abstractText
To understand the role of the eosinophilopoietic cytokine IL-5 in humans, the posttreatment eosinophilic response in a group of microfilaria (mf)-positive patients with onchocerciasis (n = 10) was examined before and after treatment with diethylcarbamazine (6 mg/kg for 7 d). Sequential blood samples were assessed at 24 and 1 h before treatment (baseline values), then at frequent intervals over the next 14 d. Symptom scores, skin microfilariae (mf), and peripheral blood eosinophil counts were recorded as a function of time after treatment, and serum levels of IL-5 were quantitated by a highly sensitive (sensitivity greater than or equal to 20 pg/ml) monoclonal-based ELISA. Pretreatment eosinophil counts ranged from 240 to 1,186 eosinophils/microliter (geometric mean, 675), and the mf counts from 10 to 218 per mg skin (geometric mean, 79). After an initial decline in the peripheral eosinophil count to 28 +/- 8% of pretreatment levels at 8 h after beginning treatment, the eosinophil counts steadily increased over the next 2 wk, reaching a maximum at 14 d (257 +/- 38% of pretreatment levels). Serum levels of IL-5 rose sharply from pretreatment levels to a peak of 70.5 +/- 11 pg/ml by 24 h after treatment. Serum IL-5 remained elevated over the next 2-3 d and declined toward baseline by approximately 6 d after treatment, at which time the eosinophil levels were steadily increasing. IL-3 and granulocyte macrophage colony-stimulating factor, two other cytokines implicated in eosinophilopoeisis, were not detectable in the serum at any time before or after treatment. The rise in serum IL-5 before the posttreatment eosinophilia seen in this group of patients with onchocerciasis demonstrates a temporal relationship between IL-5 and the subsequent development of eosinophilia and implicates IL-5 as an important mediator of eosinophilia in humans.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-1706953, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-2104985, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-2193099, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-2236076, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-2369637, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-2405493, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-2653458, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-2785414, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-2787385, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-2787531, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-3258425, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-3305722, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-4003668, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-448186, http://linkedlifedata.com/resource/pubmed/commentcorrection/1918387-7021674
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0021-9738
pubmed:author
pubmed:issnType
Print
pubmed:volume
88
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1418-21
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis.
pubmed:affiliation
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't